All In Biotech

Drug Trial Radar · NCT05252364

A Study to Assess the Safety, Pharmacokinetics, and Anti-Tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

A Phase 1 Open-Label Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of Oral HP518 in Patients With Metastatic Castration-Resistant Prostate Cancer

Last checked: Nov 19, 2026Latest source record: Mar 21, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

22

Actual

Start

Dec 14, 2021

Primary completion

Jan 22, 2024

Study completion Jan 22, 2024

Sponsor

Sponsor type
Industry
First posted
Feb 23, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The overall objective of this Phase 1 study is to evaluate the safety, PK, and anti-tumor activity of 12 weeks of daily oral dosing with HP518 after selecting the RP2D of HP518 based on assessments of multiple dose escalation in patients with progressive mCRPC.

Conditions

  • Metastatic Castration-resistant Prostate Cancer

Interventions

  • HP518 - Dose EscalationDrug

    Part 1: Dose escalation Daily oral dosage with the prescribed dose level based on Cohort assignment.

  • HP518 - Dose expansionDrug

    Part 2: Dose expansion Daily oral dosage with the highest dose with acceptable toxicity (RP2D) based on data from Part 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidences of Protocol-defined DLT during the DLT assessment period , characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousness, and relationship to study drugTime frame: 28 days
  2. Incidence of Treatment-Emergent Adverse Events characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), timing, seriousnessTime frame: Through study completion, an average of 1 year
  3. Incidence of laboratory abnormalities, characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Through study completion, an average of 1 year
  4. Incidence of vital signs abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Time Frame: Through study completion, an average of 1 year
  5. Incidence of ECG (PR, QRS, QT, and QTcF intervals) abnormalities characterized by type, frequency, severity (as graded by NCI CTCAE version 5.0), and timingTime frame: Through study completion, an average of 1 year
  6. Proportion of patients showing a PSA decline of ≥50% between baseline and Week 12 of dosing with HP518.Time frame: 12 weeks

Locations

5 sites in 1 country. Site status is shown where the registry gives one.

  • Border Medical Oncology

    Albury, New South Wales, Australia

  • Chris O'Brien Lifehouse

    Camperdown, New South Wales, Australia

  • Macquarie University

    Macquarie Park, New South Wales, Australia

  • Peter McCallum Cancer Center

    Melbourne, Victoria, Australia

  • Alfred Hospital

    Melbourne, Victoria, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.